Treatment of oestrogen deficiency symptoms in postmenopausal women, >1 yr after menopause. Prevention of osteoporosis in postmenopausal women at high risk of future fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of osteoporosis.
View Livial overdosage for action to be taken in the event of an overdose.
Administration
May be taken with or without food: Swallow w/ some water or other drink.
Contraindications
Hypersensitivity. Known, past or suspected breast cancer; known or suspected oestrogen-dependent malignant tumours; undiagnosed genital bleeding; untreated endometrial hyperplasia. Previous or current VTE; known thrombophilic disorders; any history of arterial thromboembolic disease. Acute liver disease or history of liver disease as long as LFTs have failed to return to normal. Porphyria. Pregnancy & lactation.
Do not add a separate progestogen. Investigate any irregular/unscheduled vag bleeding to exclude malignancy before starting treatment. Initiate treatment only for postmenopausal symptoms that adversely affect quality of life. Limited evidence regarding risks in treatment of premature menopause. Not intended for contraceptive use. Conditions that may recur or be aggravated during treatment: Leiomyoma or endometriosis; risk factors for thromboembolic disorders; risk factors for oestrogen-dependent tumours; HTN; liver disorders; DM w/ or w/o vascular involvement; cholelithiasis; migraine or severe headache; SLE; history of endometrial hyperplasia; epilepsy; asthma; otosclerosis. Discontinue treatment in case of jaundice or deterioration in liver function; significant increase in BP; new onset of migraine-type headache. Risk of endometrial hyperplasia & carcinoma; breast cancer; ovarian cancer; VTE; ischaemic stroke. Very minor decrease of thyroid-binding globulin & total T4. Decreased level of sex-hormone-binding globulin. Risk of probable dementia in women who start using continuous combined or oestrogen-only HRT after age of 65. Caution in patients w/ cardiac or renal dysfunction; women w/ pre-existing hypertriglyceridaemia. Should not be taken by patients w/ rare hereditary problems of galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption. No relevant use in paed population.
Sign Out
